Title compds. I and II [Z = N or CR2; each R1 independently = H, alkyl, haloalkyl, or alkoxyalkyl; or together are CH2CH2, (CH2)3, (CH2)4, or (CH2)5; R2 = H, alkyl, alkoxy, or cycloalkyl; R3 = H, alkyl, halo, alkoxy, etc.; each R4 independently = OH, CN, alkyl, etc.; R5 = H, alkyl, CN, haloalkyl, etc.; R6 = H, halo, alkyl, CN, etc.; R7 = alkyl, haloalkyl, (un)substituted cycloalkyl, etc.; R10 = H, alkyl, cycloalkyl, piperidinyl, etc.; R11 = H, alkyl, or cycloalkyl], and their pharmaceutically acceptable salts, are prepd. and disclosed as serine/threonine PAK1 inhibitors. Thus, e.g., III was prepd. by a multistep procedure (prepn. given). Select I and II were evaluated in GST-PAK1-KD (kinase domain) biochem. assays (data given).
Please note: Abstracts and Titles for patent records in CAplus are routinely enhanced to better describe the claimed invention. The title of the U.S. granted patent is Processes for making hydrazides.